INTERIM REPORT JANUARY-SEPTEMBER 2007

INTERIM REPORT JANUARY-SEPTEMBER 2007

• Group revenues from sales of goods and royalties amounted to 981.7 (972.2)
MSEK during the period.

• Growth within the Esthetics product area was 18 percent and revenues amounted
to 800.4 (680.3) MSEK.

• Operating income amounted to 381.2 (259.2) MSEK and the operating margin was
39 (29) percent.

• Income after tax amounted to 329.1 (186.7) MSEK.

• Earnings per share after full dilution were 3.31 (1.88) SEK.

• In September Q-Med obtained sales approval for MACROLANETM VRF in Europe.

July - September
• Group revenues from sales of goods and royalties amounted to 316.7 (286.0)
MSEK during the third quarter and operating income amounted to 63.0 (46.3) MSEK.

• Income after tax amounted to 45.1 (35.3) MSEK during the third quarter.


Queries should be addressed to:

Erika Kjellberg Eriksson, Vice President and CFO
Tel: +46 (0)70-974 9020
Madelene Sandgren, Director Investor Relations and Corporate Communications
Tel: +46 (0)70-974 9015

Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets and sells primarily medical
implants. The majority of the products are based on the company's patented
technology, NASHA™ for the production of stabilized non-animal hyaluronic acid. 
The product portfolio today contains: RESTYLANE for the filling out of lips and
facial wrinkles and for facial contouring, MACROLANE for body contouring,
DUROLANE  for the treatment of osteoarthritis of the hip and knee joints, DEFLUX
for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary
bladder) in children, ZUIDEX, for the treatment of stress urinary incontinence
in women and SOLESTA, for the treatment of fecal incontinence. Sales are made
through the company's own subsidiaries or distributors in over 70 countries.
Q-Med today has just over 700 co-workers, with close to 500 at the company's
head office and production facility in Uppsala, Sweden. Q-Med AB is listed in
the Large Cap segment of the OMX Nordic Exchange in Stockholm.